2023年欧洲内科肿瘤学（ESMO）大会将于欧洲中部夏令时间10月20日至24日以线上结合线下的形式在西班牙马德里盛启。基于当前ESMO官网公布的摘要内容，抗体-药物偶联物（ADC）相关研究颇多1。【肿瘤资讯】特此整理，以飨读者。
概述
尽管ESMO当前只公布了Oral Abstracts和Mini Oral Abstracts的信息，尚无LBAs内容，但仍可看出ADC相关研究的占比较高。所有ADCs主要分为两类：一是循德曲妥珠单抗之迹继续以HER2为靶点；二是另辟蹊径探寻其他靶点，如ErbB家族的其他成员HER3以及TROP2等。除此之外，ADCs中还出现了全新的靶点如CDH6、Nectin-4等2（表.ADC相关ESMO摘要一览表）。
研究及产品信息
实体瘤
摘要号及题目：385MO-A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors
产品及靶点：DP303c（HER2 ADC）
企业：石药集团（CSPC Pharmaceutical）
摘要号及题目：658MO - Phase 1 study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors
产品及靶点：SHR-A2009(HER3 ADC)
企业：江苏恒瑞
摘要号及题目：381MO - First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors
产品及靶点：HS-20089(B7-H4 ADC)
企业：上海瀚森
摘要号及题目：659MO - Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting Nectin-4, in patients with advanced solid tumors
产品及靶点：9MW2821（Nectin-4 ADC）
企业：迈威（Mabwell）
摘要号及题目：657MO - Recommended phase 2 dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors
产品及靶点：BDC-1001（HER2偶联TLR7/8激动剂）
企业：Bolt Biotherapeutics
摘要号及题目：660MO - First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase 1 study (SGNB7H4V-001)
产品及靶点：SGN-B7H4V（B7-H4 ADC）
企业：Seagen
肺癌
摘要号及题目：1319MO - Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: results from HERTHENA-Lung01
产品及靶点：Patritumab deruxtecan（HER3 ADC）
企业：第一三共（Daiichi Sankyo）
摘要号及题目：1315MO - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
产品及靶点：zenocutuzumab（HER2 x HER3双特异性抗体）
企业：Merus
摘要号及题目：1317MO - Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
产品及靶点：pelcitoclax（BCL-2/BCL-XL抑制剂）
企业：亚盛医药（Ascentage Pharma）
摘要号及题目：1318MO - First-in-Human Study of ABBV-637, an EGFR-targeting BCL-XL–Inhibiting Antibody-Drug Conjugate Combined With Osimertinib (OSI) in Relapsed/Refractory, EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
产品及靶点：ABBV-637（EGFR x BCL-XL ADC）
企业：艾伯维（AbbVie）
摘要号及题目：1314MO - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
产品及靶点：Datopotamab deruxtecan（TROP2 ADC）
企业：第一三共/阿斯利康（Daiichi Sankyo/AstraZeneca）
摘要号及题目：1990MO - Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase 2 TROPiCS-03 basket trial
产品及靶点：Sacituzumab govitecan（TROP2 ADC）
企业：吉利德（Gilead）
摘要号及题目：1316MO - BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Non-Small Cell Lung Cancer: Updated results from first-in-human phase 1 study
产品及靶点：BL-B01D1（EDFR x HER3双特异性抗体）
企业：四川百利/西雅图免疫（Systimmune）
摘要号及题目：656MO - The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): results from the global phase 1 study
产品及靶点：SHR-A1811（HER2 ADC）
药企：江苏恒瑞
乳腺癌
摘要号及题目：380MO - SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial
产品及靶点：SKB264（TROP2 ADC）
企业：默沙东（Merck & Col Kelur）
摘要号及题目：386MO - Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial
产品及靶点：Trastuzumab duocarmazine（HER2 ADC）
企业：Byondis
卵巢癌
摘要号及题目：745MO - Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase 1 study
产品及靶点：Raludotatug deruxtecan（CDH6 ADC）
企业：第一三共（Daiichi Sankyo）
鼻咽癌
摘要号及题目：860MO - MRG003, a novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic Nasopharyngeal Carcinoma
产品及靶点：MRG003（EGFR ADC）
企业：上海美雅柯（Shanghai Miracogen）
1.ESMO Congress 2023 - Conference Calendar - ESMO Congress 2023. https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/presentation/list?
2.ESMO 2023 preview – conjugates, bispecifics and more. https://www.oncologypipeline.com/apexonco/www.apexonco.com.
排版编辑：肿瘤资讯-Astrid
苏公网安备32059002004080号
